Literature DB >> 25328157

Astaxanthin lowers plasma TAG concentrations and increases hepatic antioxidant gene expression in diet-induced obesity mice.

Yue Yang1, Tho X Pham1, Casey J Wegner1, Bohkyung Kim1, Chai Siah Ku1, Young-Ki Park1, Ji-Young Lee1.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is significantly associated with hyperlipidaemia and oxidative stress. We have previously reported that astaxanthin (ASTX), a xanthophyll carotenoid, lowers plasma total cholesterol and TAG concentrations in apoE knockout mice. To investigate whether ASTX supplementation can prevent the development of NAFLD in obesity, male C57BL/6J mice (n 8 per group) were fed a high-fat diet (35%, w/w) supplemented with 0, 0.003, 0.01 or 0.03% of ASTX (w/w) for 12 weeks. The 0.03% ASTX-supplemented group, but not the other groups, exhibited a significant decrease in plasma TAG concentrations, suggesting that ASTX at a 0.03% supplementation dosage exerts a hypotriacylglycerolaemic effect. Although there was an increase in the mRNA expression of fatty acid synthase and diglyceride acyltransferase 2, the mRNA levels of acyl-CoA oxidase 1, a critical enzyme in peroxisomal fatty acid β-oxidation, exhibited an increase in the 0.03% ASTX-supplemented group. There was a decrease in plasma alanine transaminase (ALT) and aspartate transaminase (AST) concentrations in the 0.03% ASTX-supplemented group. There was a significant increase in the hepatic mRNA expression of nuclear factor erythroid 2-related factor 2 and its downstream genes, which are critical for endogenous antioxidant mechanism, in the 0.03% ASTX-supplemented group. Furthermore, there was a significant decrease in the mRNA abundance of IL-6 in the primary splenocytes isolated from the 0.03% ASTX-supplemented group upon lipopolysaccharide (LPS) stimulation when compared with that in the splenocytes isolated from the control group. In conclusion, ASTX supplementation lowered the plasma concentrations of TAG, ALT and AST, increased the hepatic expression of endogenous antioxidant genes, and rendered splenocytes less sensitive to LPS stimulation. Therefore, ASTX may prevent obesity-associated metabolic disturbances and inflammation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25328157     DOI: 10.1017/S0007114514002554

Source DB:  PubMed          Journal:  Br J Nutr        ISSN: 0007-1145            Impact factor:   3.718


  23 in total

1.  Comparison of Carotenoids for Their Antifibrogenic Effects in Hepatic Stellate Cells.

Authors:  Minkyung Bae; Mi-Bo Kim; Hyunju Kang; Young-Ki Park; Ji-Young Lee
Journal:  Lipids       Date:  2019-05-29       Impact factor: 1.880

Review 2.  Food components with antifibrotic activity and implications in prevention of liver disease.

Authors:  Minkyung Bae; Young-Ki Park; Ji-Young Lee
Journal:  J Nutr Biochem       Date:  2017-11-16       Impact factor: 6.048

3.  Nutritional programming by maternal diet alters offspring lipid metabolism in a marine teleost.

Authors:  Zhenxin Hou; Xiyuan Lu; Stefano Tiziani; Lee A Fuiman
Journal:  Fish Physiol Biochem       Date:  2022-04-11       Impact factor: 2.794

4.  Astaxanthin attenuates hepatic steatosis in high-fat diet-fed rats by suppressing microRNA-21 via transactivation of nuclear factor erythroid 2-related factor 2.

Authors:  Abdullah S Shatoor; Suliman Al Humayed; Hussain M Almohiy
Journal:  J Physiol Biochem       Date:  2021-10-15       Impact factor: 4.158

Review 5.  Lipid profile and glucose changes after supplementation with astaxanthin: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Sorin Ursoniu; Amirhossein Sahebkar; Maria-Corina Serban; Maciej Banach
Journal:  Arch Med Sci       Date:  2015-04-23       Impact factor: 3.318

Review 6.  Potential Anti-Atherosclerotic Properties of Astaxanthin.

Authors:  Yoshimi Kishimoto; Hiroshi Yoshida; Kazuo Kondo
Journal:  Mar Drugs       Date:  2016-02-05       Impact factor: 5.118

Review 7.  Relevant Aspects of Nutritional and Dietary Interventions in Non-Alcoholic Fatty Liver Disease.

Authors:  Maria Catalina Hernandez-Rodas; Rodrigo Valenzuela; Luis A Videla
Journal:  Int J Mol Sci       Date:  2015-10-23       Impact factor: 5.923

Review 8.  Astaxanthin as a Potential Protector of Liver Function: A Review.

Authors:  Jui-Tung Chen; Kazuhiko Kotani
Journal:  J Clin Med Res       Date:  2016-08-30

9.  Prevention and Treatment of Atherosclerosis: The Use of Nutraceuticals and Functional Foods.

Authors:  Francesco Visioli; Andrea Poli
Journal:  Handb Exp Pharmacol       Date:  2022

10.  Improved Hepatoprotective Effect of Liposome-Encapsulated Astaxanthin in Lipopolysaccharide-Induced Acute Hepatotoxicity.

Authors:  Chun-Hung Chiu; Chun-Chao Chang; Shiang-Ting Lin; Charng-Cherng Chyau; Robert Y Peng
Journal:  Int J Mol Sci       Date:  2016-07-14       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.